FCX-013

DB18218InvestigationalCell transplant therapies

FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).

Code names
FCX-013

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of FCX-013, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In